1ST-LINE AND SALVAGE THERAPY OF METASTATIC BREAST-CANCER WITH MITOMYCIN VINBLASTINE

被引:0
|
作者
SEDLACEK, SM [1 ]
机构
[1] ROSE MED CTR,ROSE BREAST CTR,DENVER,CO 80220
关键词
MITOMYCIN; SALVAGE THERAPY; 1ST-LINE THERAPY; METASTATIC BREAST CANCER;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The combination chemotherapy regimen of mitomycin/vinblastine has been used in the treatment of metastatic breast cancer since the early 1980s. We report results of use of mitomycin/vinblastine in 35 women with metastatic breast cancer who had failed prior treatment with one to four chemotherapeutic regimens. Despite heavy prior treatment and significant tumor burdens, 34% of patients achieved a partial remission and another 14% had disease stabilization with a very acceptable toxicity profile. This regimen was also used for the first time as first-line chemotherapy in 11 women with metastatic breast cancer. Response was observed in 9 of 11 patients (82%). Hemolytic-uremic syndrome occurred in 6 of the 46 women (13%) treated in the two protocols and is the most serious potential complication. Mitomycin/vinblastine is an effective salvage regimen and an excellent first-line chemotherapeutic treatment for women with metastatic breast cancer.
引用
收藏
页码:16 / 23
页数:8
相关论文
共 50 条
  • [31] MITOMYCIN-C AND VINBLASTINE IN THE TREATMENT OF ADVANCED BREAST-CANCER
    RADFORD, JA
    RUBENS, RD
    BRITISH JOURNAL OF CANCER, 1985, 51 (04) : 597 - 597
  • [32] SALVAGE CHEMOTHERAPY FOR METASTATIC BREAST-CANCER
    HORTOBAGYI, GN
    SEMINARS IN HEMATOLOGY, 1987, 24 (02) : 56 - 61
  • [33] MITOMYCIN-C AND VINBLASTINE IN THE TREATMENT OF ADVANCED BREAST-CANCER
    RADFORD, JA
    KNIGHT, RK
    RUBENS, RD
    EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1985, 21 (12): : 1475 - 1477
  • [34] MITOMYCIN-C AND VINBLASTINE CHEMOTHERAPY FOR ADVANCED BREAST-CANCER
    KONITS, PH
    AISNER, J
    VANECHO, DA
    LICHTENFELD, K
    WIERNIK, PH
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1980, 21 (MAR): : 410 - 410
  • [35] SALVAGE CARBOPLATIN THERAPY FOR ADVANCED OVARIAN-CANCER AFTER 1ST-LINE TREATMENT WITH CISPLATIN
    WILLIAMS, LL
    FUDGE, M
    BURNETT, LS
    JONES, HW
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (04): : 331 - 336
  • [36] MITOMYCIN, DOXORUBICIN, AND VINBLASTINE AS 2ND-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED BREAST-CANCER
    BOROVIK, R
    EPELBAUM, R
    COHEN, Y
    ROBINSON, E
    CANCER TREATMENT REPORTS, 1986, 70 (04): : 517 - 518
  • [37] HIGH-DOSE MEDROXYPROGESTERONE ACETATE VERSUS OOPHORECTOMY AS 1ST-LINE THERAPY OF ADVANCED BREAST-CANCER IN PREMENOPAUSAL PATIENTS
    MARTONI, A
    LONGHI, A
    CANOVA, N
    PANNUTI, F
    ONCOLOGY, 1991, 48 (01) : 1 - 6
  • [38] Time-to-failure in 1st-line endocrine therapy with ER+/HER2-metastatic breast cancer
    Nishimura, S.
    Akiyoshi, S.
    Koga, C.
    Oikawa, M.
    Nskamura, Y.
    Ishida, M.
    Ohno, S.
    BREAST, 2015, 24 : S82 - S83
  • [39] 1ST-LINE CHEMOTHERAPY OF SUPERFICIAL BLADDER-CANCER - MITOMYCIN VS THIOTEPA
    HENEY, NM
    UROLOGY, 1985, 26 (04) : 27 - 29
  • [40] PHASE-II TRIAL OF PREDNIMUSTINE AS 1ST-LINE CHEMOTHERAPY IN PATIENTS WITH ADVANCED BREAST-CANCER
    RANKIN, EM
    HARVEY, C
    KNIGHT, RK
    RUBENS, RD
    CANCER TREATMENT REPORTS, 1987, 71 (11): : 1107 - 1108